Gritstone Oncology made a splash in 2015 with a $120m Series A venture capital round to fund the development of personalized neoantigen-targeting vaccines, and now the company has followed up with a $92.7m Series B round at a time of increasing interest in individualized immunotherapies.
Emeryville, Calif.-based Gritstone spent the past two years building its library of neoantigen data as well as its specialized manufacturing...






